

Lamivudine/Nevirapine/Zidovudine  
30mg/50mg/60mg dispersible tablets,  
(Strides Pharma Science Limited)  
HA557

WHOPAR part 5

February 2020

## **LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**Carton box/HDPE bottle**

**1. NAME OF THE MEDICINAL PRODUCT**

Lamivudine/Nevirapine/Zidovudine dispersible Tablets 30/50/60 mg \*

**2. STATEMENT OF ACTIVE SUBSTANCE**

Each dispersible tablet contains 30 mg lamivudine, 50 mg nevirapine and 60 mg zidovudine.

**3. LIST OF EXCIPIENTS**

Contains lactose monohydrate  
See patient information leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

60 dispersible tablets

**5. METHOD AND ROUTE OF ADMINISTRATION**

Oral use  
Read the patient information leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

Keep out of the reach and sight of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C, Protect from light and moisture.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE SUPPLIER**

Strides Pharma Science Limited,  
Strides House, Bilekahalli,  
Bannerghatta Road  
Bangalore, 560076  
India.  
Tel: +91-80-67840738/290  
Email: [sadiq.basha@strides.com](mailto:sadiq.basha@strides.com)

**12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)**

HA557

**13. MANUFACTURER'S BATCH NUMBER**

<Batch> {number}

**14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**